NEWS: Sanders Statement on Medicare Limiting Coverage for Alzheimer’s Drug
WASHINGTON, Jan 11 – Sen. Bernie Sanders (I-Vt.) Tuesday issued the following statement after the Centers for Medicare and Medicaid Services proposed a rule that would cover Aduhelm, the outrageously expensive Alzheimer’s treatment, and similar drugs in development only for people enrolled in qualifying clinical trials: “Biogen’s outrageous original price for Aduhelm, $56,000 per year, is the poster child for